A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-06

Study Completion Date

2023-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, observational study will evaluate the patient-based sentinel lymph node detection rate when using the Infracyanine® (indocyanine green) dye technique in patients undergoing surgery for breast cancer.

The study will describe the demographic, clinical, and tumour characteristics of patients with breast cancer undergoing surgery.

The study will describe the characteristics of how the indocyanine green dye technique is used including the dose and volume of dye used, the number and type of injection sites used to give the dye, the equipment used to detect the dye and locate the sentinel lymph node, and whether indocyanine green is used on its own or with other dyes (blue dye and/or 99mTechnetium dye).

The study will evaluate the characteristics of sentinel lymph node biopsy procedures performed using indocyanine green dye including the number of biopsies performed, the time taken to detect the sentinel lymph node and perform the biopsy, and how many sentinel lymph nodes are detected using indocyanine green dye, blue dye, and 99mTechnetium dye.

The study will also assess the safety of using indocyanine green dye for 6 weeks following surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer

NCT06378944

Breast Cancer

RECRUITING

Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer

NCT07146295

Breast Cancer Sentinel Lymph Node Biopsy (SLNB) Sentinel Lymph Node Detection +6 more

RECRUITING NA

Identification of Sentinel Lymph Nodes Using Indocyanine Green in Breast Cancer Patients

NCT07311278

Breast Cancer

ACTIVE_NOT_RECRUITING NA

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

NCT02997553

Breast Carcinoma Head and Neck Cancer Melanoma (Skin) +7 more

COMPLETED PHASE3

Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy

NCT02032563

Breast Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sentinel lymph node identification

Intervention description: Intraoperative identification of sentinel lymph node

Intervention Type PROCEDURE

indocyanine green

Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route

Intervention Type DRUG

methylene blue

1%), 2-5 mL administered by periareolar or peritumoural route

Intervention Type DRUG

Technetium (99mTc)

(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* Aged ≥18 years
* Undergoing breast cancer surgery with an indication for sentinel lymph node biopsy
* Receiving Infracyanine® (indocyanine green; alone or in combination with blue dye or 99mTc) for intraoperative identification of sentinel lymph node according to the Summary of Product Characteristics

Exclusion Criteria

* Male
* Pregnant or nursing female
* Previous allergy to indocyanine green or to any excipients
* Already included in a surgical trial
* Patient opposed to collection and processing of their data

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No